Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV SOSIP v8.2 763 vaccine
- Development stage
- Preclinical
- Lead developer
- Fundació Clínic per a la Recerca Biomèdica
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HIV SOSIP v8.2 763 is a recombinant protein subunit vaccine candidate designed for the prevention of HIV-1 infection. It consists of a stabilized, soluble HIV-1 envelope (Env) trimer derived from the 763 isolate, a Clade B strain identified in Spain. The vaccine utilizes the 'SOSIP' architecture, which incorporates a disulfide bond (SOS) and an isoleucine-to-proline mutation (IP) to maintain the trimer in its native-like, prefusion-closed conformation. The 'v8.2' iteration includes additional stabilizing mutations (such as E64K and A316W) to enhance the presentation of broadly neutralizing antibody (bNAb) epitopes while masking non-neutralizing epitopes on the trimer base. Developed by researchers at IDIBAPS and the Consorcio Centro de Investigación Biomédica en Red (CIBER), this immunogen aims to elicit broadly neutralizing antibodies against diverse HIV-1 strains.
- Other names
- 763 SOSIP trimerHIV-1 763 SOSIP v8.2HIV1 763 SOSIP v8.2HIV 1 763 SOSIP v8.2
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on HIV SOSIP v8.2 763 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV SOSIP v8.2 763 vaccine.